8-K: AnaptysBio Reports Q2 2026 Results, Jemperli Sales Surge

AnaptysBio announced strong second quarter and transitional fiscal year 2026 financial results, highlighted by significant year-over-year growth in Jemperli global net sales and positive interim trial results for Jemperli in rectal cancer.

Summary

• AnaptysBio reported financial results for the three months and transitional fiscal year ended June 30, 2026.
• Jemperli, a collaboration with GSK, showed robust growth with global net sales of $331 million for Q2 2026 (26% YoY growth) and $644 million for the first six months of 2026 (34% YoY growth).
• The company anticipates Jemperli royalties to AnaptysBio to reach over $390 million annually by 2029, based on GSK's peak monotherapy sales guidance of over $2.7 billion.
• Positive interim results from the pivotal AZUR-1 trial of Jemperli in dMMR/MSI-H locally advanced rectal cancer were announced, with an FDA PDUFA action date set for February 2027.
• AnaptysBio expects FDA approval for Quimilza (imsidolimab) in GPP in December 2026.
• The company reported net income from continuing operations of $177.3 million for Q2 2026, a significant increase from $5.7 million in Q2 2025.
• Cash, cash equivalents, and investments totaled $164.1 million as of June 30, 2026, a decrease of $47.5 million from December 31, 2025.
• A litigation with GSK and Tesaro is ongoing, with a judgment anticipated in Q4 2026 or Q1 2027.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, driven by strong Jemperli sales growth and promising regulatory updates, though tempered by ongoing litigation and a decrease in cash reserves.

Positives

• Jemperli global net sales for the six months ended June 30, 2026, reached $644 million, representing 34% year-over-year growth.
• Positive interim results from the pivotal AZUR-1 trial of Jemperli in untreated stage II/III dMMR/MSI-H locally advanced rectal cancer were announced.
• FDA PDUFA action date for Jemperli in rectal cancer is February 2027, with eligibility for expedited review.
• AnaptysBio expects FDA approval for Quimilza in GPP in December 2026.
• Net income from continuing operations was $177.3 million for the three months ended June 30, 2026, compared to $5.7 million for the same period in 2025.
• Collaboration revenue increased to $27.5 million for Q2 2026 from $22.3 million in Q2 2025, driven by Jemperli royalties.
• The company received an FDA Commissioners National Priority Voucher (CNPV) in November 2025 for Jemperli.

Negatives

• Cash, cash equivalents, and investments decreased by $47.5 million to $164.1 million as of June 30, 2026, primarily due to operating activities.
• General and administrative expenses increased significantly to $16.0 million in Q2 2026 from $4.0 million in Q2 2025, largely due to legal costs.
• The company has an outstanding debt monetization of approximately $299 million related to Sagard, anticipated to be paid down in the second half of 2027.
• The ongoing litigation with GSK and Tesaro introduces uncertainty regarding the reversion of Jemperli rights.

Risks

• The outcome of the ongoing litigation with GSK and Tesaro, which could result in the reversion of Jemperli rights.
• Potential delays in FDA decisions or regulatory approvals for Jemperli and Quimilza.
• Commercial success of Jemperli and Quimilza in their respective indications.
• The company's ability to operate efficiently with a limited staff following the separation from First Tracks Biotherapeutics.
• Risks and uncertainties related to future royalty amounts and sales milestones.
• The potential for future clinical trial results to differ from expectations.

Future Outlook

AnaptysBio anticipates continued sales acceleration for Jemperli ex-US, with major catalysts including anticipated FDA approval in dMMR/MSI-H neoadjuvant rectal cancer and a judgment in the GSK/Tesaro litigation within the next six months. FDA approval for Quimilza in GPP is expected in December 2026. The company expects to achieve over $390 million in annualized Jemperli royalties by 2029 and anticipates paying down its remaining Sagard debt monetization in the second half of 2027.

Management Comments

• Jemperli continues to demonstrate robust year-over-year growth with major catalysts within the next 6 months including further sales acceleration ex-US, anticipated FDA approval of Jemperli in monotherapy in dMMR/MSI-H neoadjuvant rectal cancer, as well as a judgement expected in our litigation with GSK and Tesaro.
• In addition to Jemperli, we anticipate FDA approval of Quimilza in GPP in December 2026.

Industry Context

StockSavvy.ai notes that the strong performance of Jemperli aligns with the growing market for immuno-oncology drugs, particularly in indications like dMMR/MSI-H cancers. The company's focus on managing financial collaborations and returning value through royalties is a common strategy in the biotech sector, especially for companies with a portfolio of licensed assets.

Comparison to Industry Standards

• GSK's Jemperli global net sales growth of 26% YoY for Q2 2026 and 34% YoY for the first six months of 2026 are strong figures, outperforming many established oncology drugs in mature markets, but in line with high-growth specialty therapeutics.
• The projected peak monotherapy sales guidance for Jemperli of over $2.7 billion by GSK places it among the top-tier oncology assets, comparable to other blockbuster immuno-oncology agents like Keytruda (Merck) or Opdivo (Bristol Myers Squibb) in their peak years, though direct comparison is difficult due to different indications and market penetration stages.
• The AZUR-1 trial's positive interim results demonstrating a meaningful and sustained clinical complete response rate (cCR12) are encouraging and align with the high efficacy benchmarks sought in dMMR/MSI-H cancer treatment, where complete responses are a key differentiator.

Legal Proceedings

• Ongoing litigation with GSK and Tesaro concerning Jemperli rights. A trial was held in July 2026, with a post-trial hearing scheduled for October 20, 2026, and a judgment anticipated in Q4 2026 or Q1 2027. AnaptysBio is seeking reversion of Jemperli rights as a remedy.

Stakeholder Impact

• Shareholders: Potential for increased value through Jemperli royalty growth and successful litigation outcome, but offset by decreased cash reserves and ongoing legal costs.
• Creditors: The company anticipates paying down its Sagard debt monetization in the second half of 2027.
• Partners (GSK, Vanda): Continued collaboration and potential for significant revenue generation from Jemperli and Quimilza.

Next Steps

• GSK to present first results from the AZUR-1 trial at ESMO Congress 2026 on October 25, 2026.
• Anticipated FDA approval of Quimilza in GPP in December 2026.
• Anticipated judgment in the GSK and Tesaro litigation in Q4 2026 or Q1 2027.
• Anticipated FDA approval of Jemperli in monotherapy in dMMR/MSI-H neoadjuvant rectal cancer in February 2027.
• Paydown of the remaining ~$299 million non-recourse debt monetization in the second half of 2027.

Key Dates

Recommendation

The company shows strong growth in its key collaboration revenue stream (Jemperli) and positive clinical/regulatory developments, which are significant positives. However, the ongoing litigation with GSK and Tesaro introduces substantial uncertainty regarding future rights to Jemperli. The decrease in cash reserves and increased G&A expenses also warrant caution. Therefore, a 'hold' recommendation is appropriate, pending the resolution of the litigation and further clarity on cash burn and regulatory milestones.

Keywords

Jemperli, Quimilza, dMMR/MSI-H, rectal cancer, GPP, financial results, collaboration revenue, litigation